Vortioxetine, a multimodal antidepressant, blocks SERT and has a strong affinity for 4 serotonergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an ...

A new study published in the Journal of Alzheimer’s Disease suggests that vortioxetine, an antidepressant with a unique multimodal mechanism, may offer greater benefits for both mood and cognitive ...

Please provide your email address to receive an email when new articles are posted on . Vortioxetine more effectively improved depression, anxiety and cognition than placebo, according to study ...

On September 30, 2013, a new antidepressant, vortioxetine (Brintellix™), produced and comarketed by Lundbeck and Takeda, was approved by the US Food and Drug Administration. The recommended starting ...

H. Lundbeck A/S (Lundbeck) has announced results from FOCUS, a new study(1) showing that Brintellix (vortioxetine) 10 mg and 20 mg, met its primary endpoint in demonstrating superiority versus placebo ...

Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for ...

In a double-blind comparative study vs agomelatine, Brintellix met primary and secondary endpoints for efficacy and overall functioning in patients with major depression and inadequate response to ...

H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT ...

Trintellix Bottle In the 8-week, randomized, double-blind study, patients with depression who had TESD (N=447) while taking an SSRI (eg, paroxetine, sertraline or citalopram) were switched to ...